Recent Quotes (30 days)

You have no recent quotes
chg | %

Roche Holding Ltd. (ADR)  

(Public, OTCMKTS:RHHBY)   Watch this stock  
Find more results forPINK:RHHBY
31.14
-0.24 (-0.75%)
Feb 11 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 30.94 - 31.29
52 week 30.85 - 38.54
Open 31.28
Vol / Avg. 407,609.00/1.40M
Mkt cap 217,374.70M
P/E 23.59
Div/yield 1.03/3.31
EPS 1.32
Shares 692.02M
Beta 0.78
Inst. own 16%
May 11, 2016
Roche Holding AG at Bank of America Merrill Lynch Health Care Conference Add to calendar
May 10, 2016
Roche Holding AG at Redburn European Equity Conference Add to calendar
May 10, 2016
Roche Holding AG at Berenberg Diagnostics Conference Add to calendar
Apr 19, 2016
Q1 2016 Roche Holding AG Corporate Sales Release - 1:00am GMT-4 - Add to calendar
Mar 22, 2016
Roche Holding AG at Kepler Cheuvreux Swiss Seminar Add to calendar
Mar 16, 2016
Roche Holding AG at Exane Bnp Healthcare Conference Add to calendar
Mar 15, 2016
Roche Holding AG at Barclays Global Healthcare Conference Add to calendar
Mar 8, 2016
Roche Holding AG at Cowen Health Care Conference Add to calendar
Mar 2, 2016
Roche Holding AG at Credit Suisse One-on-One Healthcare Conference Add to calendar
Mar 1, 2016
Roche Holding AG Annual Shareholders Meeting - 4:30am GMT-5 - Add to calendar
  

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 15.50% 18.81%
Operating margin 23.30% 27.89%
EBITD margin - 40.92%
Return on average assets 10.50% 11.97%
Return on average equity 38.85% 43.70%
Employees 91,747 -
CDP Score - 99 A-

Address

Grenzacherstr. 124
BASEL, 4058
Switzerland
+41-9-732354295 (Phone)

Website links

External links

Description

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Company's Pharmaceuticals Division comprises the two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Europe, the Middle East and Africa (EMEA), and Japan. The Company focuses on a select group of disease areas, including oncology, hematology, neuroscience, immunology, inflammation, ophthalmology, infectious and rare diseases. Its key pharmaceutical products include Avastin, Herceptin, Perjeta, Kadcyla, MabThera/Rituxan, Lucentis, Actemra/RoActemra, Zelboraf and Gazyva/Gazyvaro.

Officers and directors

Severin Schwan Chairman of the Corporate Executive Committee, Chief Executive Officer, Director
Age: 48
Alan Hippe Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
Age: 48
Stephan Feldhaus Member of the Enlarged Corporate Executive Committee, Head Group Communications
Age: 53
Sophie Kornowski-Bonnet Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Age: 52
Osamu Nagayama Member of the Enlarged Corporate Executive Committee, President and Chief Executive Officer of Chugai
Age: 68
John C. Reed M.D., Ph.D. Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Age: 57
Michael David Varney Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Age: 57
Urs Jaisli Chief Compliance Officer
Age: 59
Gottlieb A. Keller Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Age: 61
Silvia Ayyoubi Member of the Corporate Executive Committee, Head of Group Human Resources
Age: 62